October 7, 1999

POSTER PRESENTATION AT NATIONAL MARROW DONOR PROGRAM (NMDP)
PERTAINING TO RESEARCH ON BIOACCESS BONE MARROW COLLECTION KIT.

BioAccess announced an abstract and poster presentation at the National Marrow Donor Program (NMDP) Annual Meeting being held October 7, 1999.

The company’s present Bone Marrow Collection Kit dramatically improved the methods used in the aspiration and collection of bone marrow. The Bone Marrow Collection Kit was the first system to be a ‘Sealed System’ and the first system recognized as a ‘Safety Device’ by EPINet, Cal/OSHA and Frontline Healthcare Workers Safety Project. The Sealed Bone Marrow Collection Kit is comprised of a sealed collection container and additional sealed secondary containers. The proprietary configuration allowed for the elimination of several steps of significant advantage, such as docking syringes or spraying marrow.

The presentation detailed an evaluation of the BioAccess Bone Marrow Collection Kit by the authors, Ellie Hamilton, MT (ASCP), Edmund K. Waller, MD, PhD, from the Bone Marrow and Stem Cell Transplant Program, Emory University Hospital, Atlanta, GA. The presentation titled ‘Single Bag Closed Collection System for Bone Marrow Harvest’ compared clinical data and user feedback from the BioAccess Bone Marrow Collection System (MH-2150) to historical controls. Results of the investigation were acceptable and the BioAccess Bone Marrow Collection Kit was an improvement according to the study.

According to the company’s design team, the Bone Marrow Collection Kit dramatically improves the methods used in the aspiration and collection of bone marrow. The Bone Marrow Collection Kit was the first system to be a ‘Sealed System’ and is cost effective for bone marrow collection centers and bone marrow transplant centers.

This document contains forward-looking statements, including without limitation, statements concerning planned product development objectives, potential product applications, and potential advantages of BioAccess products or planned products. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties. Actual results to differ materially from the statements contained herein. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. BioAccess undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. BioAccess is a privately owned medical device company incorporated in Delaware. Nothing on this page or site should be construed as an offer or solicitation to buy or sell any specific products or securities.